CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded
RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.
How this was made
The 30-second read
Why it matters
The upgrades collectively suggest a sector‑wide earnings growth narrative, which may attract fund inflows into Australian health equities.
Market read
Analyst upgrades with new price targets provide fresh actionable information for traders focused on ASX health stocks.
What to watch
Currency risk and potential regulatory changes in the immunoglobulin market could temper upside.
Background
RBC Capital Markets released a sector report highlighting better‑than‑expected performance across Australian health stocks in the August reporting season.
Ticker impact
RBC raised ResMed to Outperform with a $262 target, highlighting $1.5B annual share buybacks through FY31.
Likely modest rally of 3‑5% as buyback expectations are priced in.
Buyback guidance is a concrete catalyst but limited in scale.
RBC upgraded Fisher & Paykel to Outperform with a $52 target, citing strong FY27 guidance and double‑digit revenue growth.
Expect 5‑7% rally as investors price higher growth expectations.
Guidance upgrade is a fresh, material piece of information.
Market effects
RBC's upgrades signal broader strength in the Australian healthcare sector, potentially lifting peers.
Positive sentiment may boost ASX healthcare index performance.
Limited to investors with exposure to Australian health stocks; no direct global macro effect.
Counterpoint
Some investors may view the upgrades as premature given lingering uncertainties in the Seqirus and Vifor businesses.
Key entities
- analystRBC Capital Markets
Provider of the upgrades and price targets.
